October 9th 2025
In a study involving over 500 patients, researchers noted that the CT-based AI software led to a 24 percent increase of evaluations for aortic abdominal aneurysms within six months of detection.
Community Oncology Connections™: Beyond the Basics— Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies | Montana and Wyoming
View More
Community Oncology Connections™: Beyond the Basics—Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies | Washington
View More
Community Oncology Connections™: Beyond the Basics—Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies | Louisiana
View More
Lung Cancer Tumor Board: Enhancing Precision Medicine in NSCLC Through Advancements in Molecular Testing and Optimal Therapy Selection
View More
Community Oncology Connections™: Beyond the Basics—Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies | Nevada
View More
(CME Credit Only) New Frontiers in Immunotherapy for SCLC: Insights From Latest Clinical Trials and Their Application in Real-World Treatment
View More
(MOC and CME Credit) New Frontiers in Immunotherapy for SCLC: Insights From Latest Clinical Trials and Their Application in Real-World Treatment
View More
(MOC and CME Credit) Lung Cancer Tumor Board®: The Pivotal Role of Multimodal Therapy in Leveraging Immunotherapy for Stage I-III NSCLC When the Goal Is Cure
View More
Researchers found comparable 10-year overall survival rates for people who had computed tomography (CT) surveillance (94.7 percent) and those who had surgery for ground-glass nodules (97.6 percent), according to a new prospective study involving over 680 participants.
Current Perspectives on Prostate Cancer and Emerging Theranostic Agents, Part 1
In a recent interview, Emmanuel S. Antonarakis, M.D. discussed contributing factors to the recent American Cancer Society report about rising prostate cancer incidence and offered insights about the potential role of the radioligand agent 177Lu-PSMA-I&T for patients with mCRPC.
FDA Grants De Novo Approval for Cryoablation Treatment of Breast Cancer
In a multicenter trial, researchers found 96.3 percent of women with low-risk, early-stage breast cancer had no local recurrence after being treated with a combination of ProSense cryoablation and hormone therapy.
What a DBT Screening Study Reveals About False Positives with AI and Radiologist Assessments
In comparison to false positives with unassisted radiologist interpretations of DBT exams, AI-only false positive assessments were associated with a significantly higher total of false-positive findings as well as a 33 percent lower frequency of dense breasts, according to a new study of nearly 3,000 women who had screening DBT exams.